An update on cefepime and its future role in combination with novel β-lactamase inhibitors for MDR Enterobacterales and Pseudomonas aeruginosa
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
An update on cefepime and its future role in combination with novel β-lactamase inhibitors for MDR Enterobacterales and Pseudomonas aeruginosa
Authors
Keywords
-
Journal
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Volume -, Issue -, Pages -
Publisher
Oxford University Press (OUP)
Online
2020-12-03
DOI
10.1093/jac/dkaa511
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- In vitro efficacy of Imipenem-Relebactam and Cefepime-AAI101 against a global collection of ESBL-positive and carbapenemase-producing Enterobacteriaceae
- (2020) L. Tselepis et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Effective inhibition of PBPs by cefepime and zidebactam in the presence of VIM-1 drives potent bactericidal activity against MBL-expressing Pseudomonas aeruginosa
- (2020) Bartolome Moya et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Pharmacokinetics-Pharmacodynamics of Enmetazobactam Combined with Cefepime in a Neutropenic Murine Thigh Infection Model
- (2020) Fabian Bernhard et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pharmacodynamics of Cefepime Combined with the Novel Extended-Spectrum-β-Lactamase (ESBL) Inhibitor Enmetazobactam for Murine Pneumonia Caused by ESBL-Producing Klebsiella pneumoniae
- (2020) Adam Johnson et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In vitro activity of the novel β-lactamase inhibitor taniborbactam (VNRX-5133), in combination with cefepime or meropenem, against MDR Gram-negative bacterial isolates from China
- (2020) Xiaojuan Wang et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- The Novel β-Lactam Enhancer Zidebactam Augments the In Vivo Pharmacodynamic Activity of Cefepime in a Neutropenic Mouse Lung Acinetobacter baumannii Infection Model
- (2019) S. S. Bhagwat et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Beyond piperacillin-tazobactam: cefepime and AAI101 as a potent β-lactam-β-lactamase inhibitor combination
- (2019) Krisztina M. Papp-Wallace et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In vitro and in vivo activity of β-lactams in combination with novel β-lactam enhancers, zidebactam and WCK 5153, against multidrug-resistant metallo-β-lactamase producing Klebsiella pneumoniae
- (2019) Bartolome Moya et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In vitro activity of cefepime-enmetazobactam against Gram-negative isolates collected from United States and European hospitals during 2014-2015
- (2019) Ian Morrissey et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Effect of ampC derepression on cefepime MIC in Enterobacterales with chromosomally encoded inducible AmpC β-lactamase
- (2019) Rebekka Kohlmann et al. CLINICAL MICROBIOLOGY AND INFECTION
- Single-Center Investigation of the Pharmacokinetics of WCK 4282 (Cefepime-Tazobactam Combination) in Renal Impairment
- (2019) Richard A. Preston et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In Vivo Efficacy of WCK 5222 (Cefepime-Zidebactam) against Multidrug-Resistant Pseudomonas aeruginosa in the Neutropenic Murine Thigh Infection Model
- (2019) Marguerite L. Monogue et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pharmacokinetics-pharmacodynamics of β-lactamase inhibitors: are we missing the target?
- (2019) Marguerite L Monogue et al. Expert Review of Anti-Infective Therapy
- Activity of cefepime/zidebactam (WCK 5222) against Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter baumannii endemic to New York City medical centres
- (2019) Zeb Khan et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Clinical Impact of Revised Cefepime Breakpoint in Patients With Enterobacteriaceae Bacteremia
- (2019) Kap Sum Foong et al. Open Forum Infectious Diseases
- WCK 5222 (Cefepime-Zidebactam) Pharmacodynamic Target Analysis against Metallo-β-Lactamase-Producing Enterobacteriaceae in the Neutropenic Mouse Pneumonia Model
- (2019) Alexander J. Lepak et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Comparative Evaluation of the In Vitro Activities of WCK 5222 (Cefepime-Zidebactam) and Combination Antibiotic Therapies against Carbapenem-Resistant Pseudomonas aeruginosa
- (2019) Elias M. Mullane et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- VNRX-5133 (Taniborbactam), a Broad-Spectrum Inhibitor of Serine- and Metallo-β-Lactamases, Restores Activity of Cefepime in Enterobacterales and Pseudomonas aeruginosa
- (2019) Jodie C. Hamrick et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Evaluation of the in vitro activity of WCK 5222 (cefepime/zidebactam) and currently available combination therapies against single- and double-carbapenemase producing Enterobacteriaceae: Expanding the zone of hope
- (2019) Lindsay M. Avery et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Plasma and Intrapulmonary Concentrations of Cefepime and Zidebactam following Intravenous Administration of WCK 5222 to Healthy Adult Subjects
- (2018) Keith A. Rodvold et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Strategic Approaches to Overcome Resistance against Gram-Negative Pathogens Using β-Lactamase Inhibitors and β-Lactam Enhancers: Activity of Three Novel Diazabicyclooctanes WCK 5153, Zidebactam (WCK 5107), and WCK 4234
- (2018) Krisztina M. Papp-Wallace et al. JOURNAL OF MEDICINAL CHEMISTRY
- A Randomized Pharmacokinetic and Pharmacodynamic Evaluation of Every 8-Hour and 12-Hour Dosing Strategies of Vancomycin and Cefepime in Neurocritically ill Patients
- (2018) Lynn E. Kassel et al. PHARMACOTHERAPY
- Assessment of the In Vivo Efficacy of WCK 5222 (Cefepime-Zidebactam) Against Carbapenem-Resistant Acinetobacter baumannii in the Neutropenic Murine Lung Infection Model
- (2018) Lindsay M. Avery et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance
- (2018) Patrick N. A. Harris et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Carbapenem-Sparing Therapy for Extended-Spectrum β-Lactamase–Producing E coli and Klebsiella pneumoniae Bloodstream Infection
- (2018) Mary K. Hayden et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Single-Center Evaluation of the Pharmacokinetics of WCK 5222 (Cefepime-Zidebactam Combination) in Subjects with Renal Impairment
- (2018) Richard A. Preston et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In Vivo Efficacy of Humanized WCK 5222 (Cefepime-Zidebactam) Exposures against Carbapenem-Resistant Acinetobacter baumannii in the Neutropenic Thigh Model
- (2018) Safa S. Almarzoky Abuhussain et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Potential of high-dose cefepime/tazobactam against multiresistant Gram-negative pathogens
- (2017) David M Livermore et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- WCK 5222 (cefepime/zidebactam) antimicrobial activity tested against Gram-negative organisms producing clinically relevant β-lactamases
- (2017) Helio S. Sader et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- In vitro activity of cefepime/zidebactam (WCK 5222) against Gram-negative bacteria
- (2017) David M. Livermore et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Influence of borderline cefepime MIC on the outcome of cefepime-susceptible Pseudomonas aeruginosa bacteremia treated with a maximal cefepime dose: a hospital-based retrospective study
- (2017) Ting-Yi Su et al. Annals of Clinical Microbiology and Antimicrobials
- Cefepime Therapy for Monomicrobial Enterobacter cloacae Bacteremia: Unfavorable Outcomes in Patients Infected by Cefepime-Susceptible Dose-Dependent Isolates
- (2015) Nan-Yao Lee et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In VivoActivities of Simulated Human Doses of Cefepime and Cefepime-AAI101 against Multidrug-Resistant Gram-Negative Enterobacteriaceae
- (2015) Jared L. Crandon et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In vitro susceptibility of Escherichia colistrains isolated from urine samples obtained in mainland China to fosfomycin trometamol and other antibiotics: a 9-year surveillance study (2004–2012)
- (2014) Bei Lai et al. BMC INFECTIOUS DISEASES
- OXA-48-like carbapenemases: the phantom menace
- (2012) L. Poirel et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Breakpoints for intravenously used cephalosporins in Enterobacteriaceae—EUCAST and CLSI breakpoints
- (2008) G. Kahlmeter CLINICAL MICROBIOLOGY AND INFECTION
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started